Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
26.26
+0.56 (2.18%)
Mar 10, 2026, 10:20 AM CST
259.23%
Market Cap 12.28B
Revenue (ttm) 244.37M
Net Income (ttm) -166.17M
Shares Out 477.77M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,621,999
Average Volume 16,635,603
Open 24.76
Previous Close 25.70
Day's Range 24.76 - 26.68
52-Week Range 5.90 - 66.66
Beta 0.99
RSI 44.97
Earnings Date Mar 24, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 484
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2024, SHE:300204's revenue was 324.82 million, a decrease of -10.81% compared to the previous year's 364.18 million. Losses were -144.84 million, -63.69% less than in 2023.

Financial Statements

News

There is no news available yet.